CLAIMS

1.- A liquid pharmaceutical composition for oral administration in the form of suspension which comprises:

a) Ibuprofen in an amount comprised between 2% w/v and 10% w/v;
b) phenylephrine or a pharmaceutically acceptable salt thereof, in an amount comprised between 0.005% w/v and 2% w/v, expressed as equivalent amount of phenylephrine hydrochloride;
c) hypromellose, in an amount comprised between 0.1% w/v and 5% w/v;
d) xanthan gum, in an amount comprised between 0.05% w/v and 4% w/v;
e) liquid maltitol;
f) glycerine; and
g) water.

2.- The composition according to claim 1, characterized in that phenylephrine is in the form of a salt selected from phenylephrine hydrochloride, phenylephrine hydrobromide and phenylephrine bitartrate.

3.- The composition according to claim 2, characterized in that it comprises phenylephrine hydrochloride.

4.- The composition according to any of claims 1 to 3, characterized in that the amount of ibuprofen is comprised between 3% w/v and 5% w/v.

5.- The composition according to any of claims 1 to 4, characterized in that the amount of phenylephrine or a pharmaceutically acceptable salt thereof is comprised between 0.08% w/v and 0.2% w/v, expressed as equivalent amount of phenylephrine hydrochloride.

6.- The composition according to any of claims 1 to 5, characterized in that the amount of hypromellose is comprised between 0.2% w/v and 2% w/v, preferably comprised between 0.3% w/v and 1% w/v, more preferably comprised between 0.4% w/v and 0.6% w/v, and still more preferably is about 0.5% w/v.

7.- The composition according to any of claims 1 to 6, characterized in that the amount of xanthan gum is comprised between 0.1% w/v and 2% w/v, preferably comprised between 0.2% w/v and 1% w/v, more preferably comprised between 0.3% w/v and 0.6% w/v, and still more preferably is about 0.4% w/v.

8.- The composition according to any of claims 1 to 7, characterized in that the amount of liquid maltitol is comprised between 30% w/v and 70% w/v, preferably comprised between 35% w/v and 65% w/v, more preferably comprised between 45% w/v and 55% w/v, and still more preferably is about 50% w/v.

9.- The composition according to any of claims 1 to 8, characterized in that the amount of glycerine is comprised between 5% w/v and 15% w/v, preferably comprised between 7% w/v and 13% w/v, more preferably comprised between 9% w/v and 11% w/v, and still more preferably is about 10% w/v.

10.- The composition according to any of claims 1 to 9, characterized in that it comprises a pH adjusting agent to adjust the pH of the composition to a value comprised between 2 and 6.

11. The composition according to any of claims 1 to 10, characterized in that it comprises a preservative.

12. The composition according to any of claims 1 to 11, characterized in that it comprises a sweetening agent selected from acesulfame potassium, alitame, neohesperidin dihydrochalcone, neotame, saccharin, saccharin sodium, sucralose, thaumatin, and mixtures thereof, preferably the sweetening agent is a mixture of saccharin sodium and thaumatin.

13.- The composition according to any of claims 1 to 12, characterized in that it comprises sodium chloride, preferably in an amount comprised between 0.1% w/v to about 5% w/v.

14.- A process for preparing the composition of claims 1 to 13, characterized in that it comprises the following steps:

(i) mixing hypromellose, xanthan gum and one part of the liquid maltitol with one part of total water to obtain a homogeneous mixture;

(ii) separately mixing ibuprofen, phenylephrine or a pharmaceutically acceptable salt thereof, glycerine and the rest of liquid maltitol with another part of total water, to obtain a homogeneous mixture;

(iii) adding the mixture of step (ii) to the mixture of step (i);

(iv) adding the rest of water.

15.- The composition according to claims 1 to 13 for use in medicine, preferably for use in the treatment of symptoms of flu and common cold, such as fever, pain, sore throat, blocked nose and sinuses.